↓ Skip to main content

ProQuest

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Overview of attention for article published in British Journal of Cancer, February 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs
1 blog
twitter
5 tweeters

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
35 Mendeley